Swedish prostate cancer test to be introduced in Europe
The new Stockholm3 test, which improves prostate cancer diagnosis, gets assistance from EIT Health for a faster introduction in Europe. In a first step the test will be clinically validated in Germany, the Netherlands and Belgium. The Stockholm3 test was developed by researchers at Karolinska Institutet.
EIT Health, supported by the EU body European Innovation and Technology (EIT), will provide financing for clinical validation of the Stockholm3 test in Germany, the Netherlands and Belgium. This will be carried out together with Friedrich-Alexander-Universität, Erasmus Universitair, Academisch Ziekenhuis Groningen, Katholieke Universiteit Leuven and Universiteit Gent. The British prostate cancer foundation has previously announced that it will financially support the evaluation of the test in the British health care system.
The Stockholm3 test is a blood test that finds 20 per cent more aggressive prostate cancer while at the same time reducing the number of unnecessary biopsies by 50 per cent, compared to current clinical practice. It has been available to the Swedish healthcare since December 2016.
The Stockholm3 test combines five protein markers, over 100 genetic markers, clinical data and a decision algorithm to detect the risk of aggressive prostate cancer. The test is based on research conducted at Karolinska Institutet. It has been tried on men 50-70 years in a clinical study which included almost 60,000 participants. The results have been published in numerous scientific journals, including The Lancet Oncology, Nature Reviews Clinical Oncology and European Urology Focus.
The research to develop the Stockholm3 test was financed by the Stockholm County Council and developed in collaboration with Thermo Fisher Scientific. Professor Henrik Grönberg at Karolinska Institutet holds patent applications in the field of prostate cancer diagnostics.
For more details, visit sthlm3.se
For more information about the research, please contact:
Henrik Grönberg, MD, Professor Karolinska Institutet Phone: +46 8 52482347 or +46 70 3411356 Email: henrik.gronberg@ki.se
EIT Health is one of the largest healthcare initiatives worldwide. Its goal is to sustainably advance the fundamentals of healthcare and thus promote suitable future conditions for healthy living, active ageing and improved wellbeing of people across Europe. EIT Health leverages the expertise of more than 140 member organisations from the pharma, diagnostics and med tech fields, payers, insurances, research institutions and universities.
For more information visit: eithealth.eu
Contacts
Contact the Press Office: ki.se/pressroom
Karolinska Institutet (http://ki.se/english) is one of the world's leading medical universities. Its vision is to significantly contribute to the improvement of human health. Karolinska Institutet accounts for over 40 per cent of the medical academic research conducted in Sweden and offers the country´s broadest range of education in medicine and health sciences. The Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine.
Subscribe to releases from Karolinska Institutet - English
Subscribe to all the latest releases from Karolinska Institutet - English by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Karolinska Institutet - English
New method reveals how the brain and inner ear are formed3.4.2025 20:00:00 CEST | Pressmeddelande
Researchers at Karolinska Institutet have developed a method that shows how the nervous system and sensory organs are formed in an embryo. By labelling stem cells with a genetic ‘barcode’, they have been able to follow the cells’ developmental journey and discover how the inner ear is formed in mice. The discovery, published in Science, could provide important insights for future treatment of hearing loss.
Fluoride in drinking water is associated with impaired childhood cognition7.3.2025 15:30:00 CET | Pressmeddelande
Elevated concentrations of fluoride can occur in well water, and in some countries, it is added to drinking water to counteract caries in the population. A study from Karolinska Institutet in Sweden now supports a few previous studies indicating that exposure to fluoride during the fetal stage or early childhood may impair cognition in children. The study is published in the journal Environmental Health Perspectives.
Children with ARFID face increased risk of disease17.2.2025 17:00:00 CET | Pressmeddelande
Children with avoidant restrictive food intake disorder (ARFID) have an elevated risk of developing psychiatric and physical conditions, a new study from Karolinska Institutet published in JAMA Pediatrics reports. The study highlights the importance of early identification to improve care of these children.
Preterm babies receive insufficient pain management27.1.2025 15:29:17 CET | Pressmeddelande
A large proportion of babies born very early need intensive care, which can be painful. But the healthcare system fails to provide pain relief to the full extent. This is shown by the largest survey to date of pain in neonatal care, now published in the journal Pain.
New study paves way for immunotherapies tailored for childhood cancers20.1.2025 17:00:00 CET | Pressmeddelande
Researchers at Karolinska Institutet and the Astrid Lindgren Children’s Hospital in Sweden have determined how children’s immune systems react to different kinds of cancer depending on their age. The study, which is published in the journal Cell, reveals significant differences between the immune response of children and adults, and has the potential to lead to new tailored treatments for children with cancer.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom